...lipid rafts, though the significance of these associations is unclear. Schneider is the founder of LZ Therapeutics Inc.... ...a larger Phase II PD trial for which he hopes to obtain NIH funding. Meanwhile, LZ Therapeutics... ...and is developing LZT-1000 , a formulation of GM1, for PD and other neurological disorders. LZ Therapeutics...
...lipid rafts, though the significance of these associations is unclear. Schneider is the founder of LZ Therapeutics Inc.... ...a larger Phase II PD trial for which he hopes to obtain NIH funding. Meanwhile, LZ Therapeutics... ...and is developing LZT-1000 , a formulation of GM1, for PD and other neurological disorders. LZ Therapeutics...